Free Trial
NASDAQ:PMCB

Nuvilex 12/13/2024 Earnings Report

Nuvilex logo
$0.83 -0.02 (-2.35%)
Closing price 08/8/2025 03:47 PM Eastern
Extended Trading
$0.86 +0.03 (+3.49%)
As of 08/8/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nuvilex EPS Results

Actual EPS
-$0.29
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nuvilex Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nuvilex Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Nuvilex's next earnings date is estimated for Tuesday, August 12, 2025, based on past reporting schedules.

Conference Call Resources

Nuvilex Earnings Headlines

MyMD Pharmaceuticals Secures Strategic Investments
One stock to replace Nvidia
Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.
PharmaCyte Biotech Inc PMCB
See More Nuvilex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvilex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvilex and other key companies, straight to your email.

About Nuvilex

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex (NASDAQ:PMCB), Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

View Nuvilex Profile

More Earnings Resources from MarketBeat